Literature DB >> 2027918

Discriminative and reinforcing effects of brotizolam in rhesus monkeys.

M A Nader1, G Winger, J H Woods, W L Woolverton.   

Abstract

The reinforcing and discriminative stimulus effects of brotizolam, a benzodiazepine-hypnotic, were evaluated in rhesus monkeys. In one experiment, separate groups of monkeys (N = 3 group) were trained to discriminate pentobarbital (10 mg/kg, IG) or d-amphetamine. (0.56-1.0 mg/kg, IG) from saline, in a discrete-trials avoidance/escape paradigm. Pentobarbital (5.6-10 mg/kg), diazepam (1.0-1.7 mg/kg), and brotizolam (0.3-1.7 mg/kg) resulted in 100% drug-lever responding in all three pentobarbital-trained monkeys. In d-amphetamine-trained monkeys brotizolam administration resulted only in saline-lever responding. In another experiment, monkeys were surgically prepared with indwelling intravenous catheters and lever pressing resulted in an injection of 0.1 mg/kg/injection sodium methohexital under a fixed-ratio 10 (FR 10) schedule. Pentobarbital (0.01-0.3 mg/kg/injection) and diazepam (0.003-0.10 mg/kg/injection) maintained responding above saline control levels when substituted for methohexital. Brotizolam (0.001-0.01 mg/kg/injection) resulted in more injections received compared to saline, but fewer injections compared to pentobarbital or diazepam. Thus, results from the present experiment suggest that brotizolam would have pentobarbital-like subjective effects. However, the abuse liability of brotizolam may be lower than that for diazepam.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2027918     DOI: 10.1007/bf02244198

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Experimental abuse liability assessment of benzodiazepines.

Authors:  J H Woods
Journal:  J Psychoactive Drugs       Date:  1983 Jan-Jun

2.  Self-injection of barbiturates and benzodiazepines in baboons.

Authors:  R R Griffiths; S E Lukas; L D Bradford; J V Brady; J D Snell
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

3.  Brotizolam, a triazolothienodiazepine, in insomnia.

Authors:  K Rickels; R J Morris; R Mauriello; H Rosenfeld; H R Chung; H M Newman; W G Case
Journal:  Clin Pharmacol Ther       Date:  1986-09       Impact factor: 6.875

Review 4.  Clinical pharmacokinetics of diazepam.

Authors:  M Mandelli; G Tognoni; S Garattini
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

5.  Effects of brotizolam on the sleep of chronic insomniacs.

Authors:  M Mamelak; A Csima; V Price
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

Review 6.  Self-administration of barbiturates and benzodiazepines: a review.

Authors:  N A Ator; R R Griffiths
Journal:  Pharmacol Biochem Behav       Date:  1987-06       Impact factor: 3.533

Review 7.  Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic.

Authors:  M S Langley; S P Clissold
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

8.  Phencyclidine-like discriminative stimulus properties of opioids in the squirrel monkey.

Authors:  S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Inhibitory effects of brotizolam, a new thienodiazepine, on limbic forebrain and neostriatal dopaminergic systems in vivo and in vitro.

Authors:  J Ishiko; C Inagaki; S Takaori
Journal:  Neuropharmacology       Date:  1983-02       Impact factor: 5.250

10.  Antiemotional and anticonvulsant activity of brotizolam and its effects on motor performance in animals.

Authors:  K Böke-Kuhn; P Danneberg; F J Kuhn; E Lehr
Journal:  Arzneimittelforschung       Date:  1986-03
View more
  1 in total

1.  Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline.

Authors:  W L Woolverton; M A Nader
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.